Medication info
Igliptin Tablet 50 mg (Sitagliptin Hydrochloride Monohydrate)

Igliptin Tablet 50 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Vivozon Pharmaceutical Co., Ltd.
Appearance
Light apricot-colored, round, biconvex film-coated tablet
Packaging
PTP - 28 tablets/PTP [(14 tablets/PTP x 2)]
Approval status
Active

MFDS item code 202101299 · Approved 2021.02.16 · Insurance code 658204590

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for use, section 5. General precautions). Patients with renal impairment Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Vivozon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

  • Difficulty in controlling blood sugar in patients with type 2 diabetes
View approved original text

This medication is used to improve blood sugar control in patients with type 2 diabetes in conjunction with diet and exercise. It can be administered alone and may also be used together with metformin when monotherapy is insufficient at the initiation of drug treatment. Additionally, it is combined with sulfonylureas, metformin, thiazolidinediones, or insulin when blood sugar control is difficult with monotherapy. This drug can also be used as an add-on therapy when blood sugar control is inadequate while on combination therapy. It effectively helps to control blood sugar by appropriately adjusting combinations based on the patient's condition. Therefore, this medication is very useful in improving blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for use, section 5. General precautions). Patients with renal impairment Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication can cause severe allergic reactions, so if symptoms such as skin rash or difficulty breathing occur, discontinue use immediately and consult a doctor. During treatment with this medication, if symptoms of pancreatitis such as abdominal pain, vomiting, or severe abdominal pain occur, notify medical personnel immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in individuals who are allergic to this medication or its components. Patients with reduced renal function should have their dosage adjusted, and it is recommended to conduct regular kidney function tests. Patients may experience side effects such as cold symptoms, headache, indigestion, or diarrhea while taking this medication, and if symptoms are severe, consult a doctor. Caution is advised when taking this medication in conjunction with other hypoglycemic agents such as insulin or sulfonylureas, as the risk of hypoglycemia may increase; regular monitoring of blood glucose levels and dosage adjustment may be necessary. If symptoms of severe joint pain or skin blistering occur, discontinue this medication immediately and seek professional treatment. The use of this medication in pregnant or nursing women is not recommended, and safety and effectiveness have not been established in individuals under 18 years of age. In cases of overdose, seek appropriate medical treatment immediately, as this medication can be partially removed by hemodialysis. This drug has low interaction with other medications, but patients should inform their physician of any concurrent medications, especially when taken with cyclosporine or digoxin caution is needed. Elderly patients may have a risk of decreased renal function, so dosage adjustments and regular kidney function tests are necessary.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • nasopharyngitis
  • upper respiratory infection
  • headache
  • diarrhea
  • abdominal pain
Show 31 more
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • rash
  • urticaria
  • cutaneous vasculitis
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction
  • pneumonia
  • diabetic complications
  • metabolic acidosis
  • falls
  • cardiac arrest

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container that prevents air access, and it is best to keep it at a temperature between 1 degree and 30 degrees Celsius. Proper storage helps maintain the drug's effectiveness for a longer duration.

Appearance and packaging

Appearance

Light apricot-colored, round, biconvex film-coated tablet

Package unit

PTP - 28 tablets/PTP [(14 tablets/PTP x 2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.